Green Light – To Lilly’s Momoclonal Antibody To Migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab (Emgality) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month.

Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function


Läs artikeln på >>>